Target intelligence / Profile preview

RING finger protein 4 (RNF4)

Target
RNF4
Molecular classification
Enzyme, Ubiquitin ligase (E3), RING finger protein, SUMO-targeted ubiquitin ligase (STUbL)
01

Overview

RING finger protein 4 (RNF4) is a RING-type E3 ubiquitin ligase that acts as a SUMO-targeted ubiquitin ligase (STUbL) in humans[1][2][3][4][5][6]. RNF4 contains a RING finger domain responsible for E3 ligase activity and multiple SUMO-interacting motifs that enable it to specifically recognize and polyubiquitylate proteins modified by SUMO (small ubiquitin-like modifier), targeting them for proteasomal degradation. RNF4 plays a crucial role in the DNA damage response by promoting the repair of DNA double-strand breaks through homologous recombination and non-homologous end joining[3][5][6]. It orchestrates the turnover of DNA repair factors at sites of damage, and its deficiency leads to persistent DNA lesions, genome instability, and impaired spermatogenesis. RNF4 is also a key mediator of the therapeutic action of arsenic trioxide in acute promyelocytic leukemia, by facilitating the degradation of SUMOylated PML. Its molecular functions center on integrating the SUMO and ubiquitin pathways to maintain protein homeostasis, genome integrity, and cellular response to genotoxic stress[2][4][6].

Other names
SNURFRES4-26Protein SNURFSLX5Small nuclear ring finger proteinE3 ubiquitin-protein ligase RNF4E3 ubiquitin ligase RNF4RING-type E3 ubiquitin transferase RNF4small nuclear RING finger protein
02

Mechanism of action

Degradation of SUMOylated proteins (e.g., PML) via ubiquitin-proteasome pathway (as part of arsenic trioxide mechanism in leukemia)

03

Biological functions

Protein ubiquitylationSUMOylated substrate recognitionDNA damage responseDNA double-strand break repairRegulation of protein degradationSpermatogenesis
04

Disease associations

Cancer (implicated in genome instability, acute promyelocytic leukemia)Other (genome maintenance, DNA repair defects, sensitivity to genotoxic stress)
05

Safety considerations

Potential for adverse effects from impaired DNA repair and increased genomic instability if inhibited
06

Interacting drugs

Arsenic trioxide (indirectly, as RNF4 mediates degradation of PML in response to arsenic trioxide in acute promyelocytic leukemia)
07

Biomarkers

SUMOylated PML (for arsenic trioxide sensitivity/response in leukemia)

Beyond the preview

Go deeper on RING finger protein 4 (RNF4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RING finger protein 4 (RNF4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call